Moreover, PI3K/AKT signaling has crosstalk with MAPK/ERK signaling pathways 14, indicating that latent compensatory activation of the PI3K/AKT pathway may contribute to sorafenib resistance of HCC. This evidence concerns the gene AKT1 and hepatocellular carcinoma.